This video was made possible through sponsorship by Lexeo Therapeutics. Being Patient’s editorial team produced the interview and article, with no review/approval process by the sponsor. Lexeo Therapeutics: https://www.lexeotx.com/ Pioneering genetic medicine expert and physician Ronald G. Crystal of Cornell University’s Weill Medical College joins Being Patient’s editor in chief Deborah Kan for a discussion on gene therapy in relation to Alzheimer’s disease. As a pioneer in the field of genetic medicine, he started working in gene therapy in the late 1980s. His work has helped to form the basis for all subsequent work in adenovirus-based gene therapies and vaccines. Crystal has carried out human trials of gene therapy for diseases including cystic fibrosis, cardiac ischemia, cancer and central nervous system disorders, and most recently, he has been working on gene therapies for Alzheimer’s disease: For example, his laboratory developed a gene therapy designed to reduce the high risk of Alzheimer’s associated with the APOE4 genetic variant — aka the “Alzheimer’s gene” — a strategy that is currently in clinical trials. Crystal is the director of the Belfer Gene Therapy Core Facility and attending physician at the New York-Presbyterian Hospital/Weill Cornell Medical Center, and he chairs the Cornell University Weill Medical College genetic medicine department. He’s also responsible for a number of biomedical patents, and he’s founded multiple gene therapy-focused biotech companies including Lexeo Therapeutics, a New York City-based clinical-stage gene therapy company focused on addressing genetically defined cardiovascular and central nervous system diseases. In this Live Talk, he’ll share his expert take on the past, present future of the field with regard to neurodegenerative diseases like Alzheimer’s. This Live Talk is sponsored by Lexeo Therapeutics. YOUR TRUSTED SOURCE FOR BRAIN HEALTH NEWS AND SCIENCE. Being Patient is an editorially independent media platform publishing journalism about brain health, cognitive science, and neurodegenerative diseases like Alzheimer’s. If you learned something from this talk, find more helpful science reporting, mythbusting, and patient and caregiver stories at beingpatient.com. Follow Being Patient on social: Twitter: / being_patient_ Instagram: / beingpatientvoices Facebook: / beingpatientalzheimers LinkedIn: / being-patient Check out our latest Live Talks with medical experts, scientists, researchers, patients and caregivers here: https://www.beingpatient.com/category...

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related